NCT01777191

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 204 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Ixekizumab Auto-Injector	Administered SC by auto-injector
DRUG	Ixekizumab Prefilled Syringe	Administered SC by prefilled syringe

Timeline

• Start date: 2013-03-01
• Primary completion: 2014-05-01
• Completion: 2015-05-01
• First posted: 2013-01-28
• Last updated: 2019-09-30
• Results posted: 2016-05-26

Locations

25 sites across 2 countries: United States, Puerto Rico